{"id":22188,"date":"2026-01-21T18:40:38","date_gmt":"2026-01-22T02:40:38","guid":{"rendered":"https:\/\/drugpolicy.ca\/les-problemes\/psychedeliques\/"},"modified":"2026-01-21T18:40:38","modified_gmt":"2026-01-22T02:40:38","slug":"psychedeliques","status":"publish","type":"page","link":"https:\/\/www.drugpolicy.ca\/fr\/les-problemes\/psychedeliques\/","title":{"rendered":"Psych\u00e9d\u00e9liques"},"content":{"rendered":"\n<div class=\"wp-block-group alignwide is-layout-flow wp-block-group-is-layout-flow\">\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-794e3cfa wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:60%\">\n<p class=\"wp-block-paragraph\">Une nouvelle fronti\u00e8re pour la m\u00e9decine curative<\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:40%\"><\/div>\n<\/div>\n<\/div>\n<figure style=\"aspect-ratio:21\/9; margin-top:var(--wp--preset--spacing--50);margin-bottom:var(--wp--preset--spacing--60);\" class=\"alignwide wp-block-post-featured-image\"><img loading=\"lazy\" decoding=\"async\" width=\"2560\" height=\"1707\" src=\"https:\/\/www.drugpolicy.ca\/wp-content\/uploads\/2021\/11\/greg-rakozy-oMpAz-DN-9I-unsplash-scaled.jpg\" class=\"attachment-post-thumbnail size-post-thumbnail wp-post-image\" alt=\"Homme regardant l&#039;espace\" style=\"width:100%;height:100%;object-fit:cover;\" srcset=\"https:\/\/www.drugpolicy.ca\/wp-content\/uploads\/2021\/11\/greg-rakozy-oMpAz-DN-9I-unsplash-scaled.jpg 2560w, https:\/\/www.drugpolicy.ca\/wp-content\/uploads\/2021\/11\/greg-rakozy-oMpAz-DN-9I-unsplash-300x200.jpg 300w, https:\/\/www.drugpolicy.ca\/wp-content\/uploads\/2021\/11\/greg-rakozy-oMpAz-DN-9I-unsplash-1024x683.jpg 1024w, https:\/\/www.drugpolicy.ca\/wp-content\/uploads\/2021\/11\/greg-rakozy-oMpAz-DN-9I-unsplash-768x512.jpg 768w, https:\/\/www.drugpolicy.ca\/wp-content\/uploads\/2021\/11\/greg-rakozy-oMpAz-DN-9I-unsplash-1536x1024.jpg 1536w, https:\/\/www.drugpolicy.ca\/wp-content\/uploads\/2021\/11\/greg-rakozy-oMpAz-DN-9I-unsplash-2048x1365.jpg 2048w\" sizes=\"auto, (max-width: 2560px) 100vw, 2560px\" \/><\/figure>\n<div class=\"wp-block-group has-global-padding is-layout-constrained wp-block-group-is-layout-constrained\" style=\"margin-top:var(--wp--preset--spacing--50);margin-bottom:var(--wp--preset--spacing--50)\">\n<p class=\"wp-block-paragraph\">Un article paru r\u00e9cemment dans le <em>Journal de l&#8217;Association m\u00e9dicale canadienne<\/em>, le<sup>8<\/sup> septembre 2015, intitul\u00e9 &#8220;Psychedelic medicine : a re-emerging therapeutic paradigm&#8221;, illustre un regain d&#8217;int\u00e9r\u00eat pour l&#8217;exploration des b\u00e9n\u00e9fices de l&#8217;utilisation de substances psych\u00e9d\u00e9liques dans le traitement d&#8217;une s\u00e9rie de pathologies, notamment le syndrome de stress post-traumatique (SSPT), l&#8217;anxi\u00e9t\u00e9, les addictions et la d\u00e9pression. Ce type d&#8217;intervention th\u00e9rapeutique &#8220;r\u00e9appara\u00eet&#8221; apr\u00e8s que Richard Nixon a d\u00e9clar\u00e9 la guerre aux drogues en 1972, ce qui a eu pour effet de geler pratiquement toutes les recherches sur les avantages potentiels des substances psych\u00e9d\u00e9liques dans des contextes th\u00e9rapeutiques &#8211; dont certaines \u00e9taient en cours depuis les ann\u00e9es 1950 -, le financement de la recherche s&#8217;\u00e9tant tari et l&#8217;establishment m\u00e9dical ayant suivi les attitudes politiques dominantes \u00e0 l&#8217;\u00e9gard de cette classe de drogues. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ces derni\u00e8res ann\u00e9es, cependant, la communaut\u00e9 scientifique et la soci\u00e9t\u00e9 en g\u00e9n\u00e9ral ont manifest\u00e9 un int\u00e9r\u00eat croissant pour les utilisations b\u00e9n\u00e9fiques des psych\u00e9d\u00e9liques, une nouvelle g\u00e9n\u00e9ration de personnes cherchant \u00e0 explorer le potentiel de d\u00e9veloppement humain de substances telles que l&#8217;ayahuasca, la psilocybine, le LSD et la MDMA, pour n&#8217;en citer que quelques-unes. Du cabinet du th\u00e9rapeute aux festivals de musique en passant par les jungles amazoniennes, un mouvement d&#8217;exploration des psych\u00e9d\u00e9liques dans des contextes th\u00e9rapeutiques formels et informels est en train de se produire. Cette \u00e9volution offre aux gouvernements, aux scientifiques et aux communaut\u00e9s de r\u00e9elles possibilit\u00e9s d&#8217;\u00e9laborer des politiques qui prot\u00e8gent les consommateurs, facilitent la recherche et cr\u00e9ent des approches alternatives \u00e0 ces drogues. Plut\u00f4t que de continuer \u00e0 criminaliser et \u00e0 nier que l&#8217;utilisation prudente des psych\u00e9d\u00e9liques peut avoir des effets b\u00e9n\u00e9fiques importants, les gouvernements devraient chercher \u00e0 maximiser les avantages potentiels de ces substances pour les individus et les communaut\u00e9s.   <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Les usages th\u00e9rapeutiques et religieux des substances psych\u00e9d\u00e9liques ont longtemps pr\u00e9c\u00e9d\u00e9 nos connaissances scientifiques, et diverses cultures \u00e0 travers le monde ont travaill\u00e9 avec des substances naturelles pendant des milliers d&#8217;ann\u00e9es dans des contextes c\u00e9r\u00e9moniels et de gu\u00e9rison folklorique. La r\u00e9surgence d&#8217;\u00e9tudes scientifiques et d&#8217;essais cliniques peut apporter des connaissances pour de nouvelles approches th\u00e9rapeutiques, qui seraient un compl\u00e9ment bienvenu aux traitements actuellement limit\u00e9s disponibles dans le domaine de la sant\u00e9 mentale et de la toxicomanie. En effet, les preuves scientifiques renouvel\u00e9es sur les psych\u00e9d\u00e9liques sugg\u00e8rent qu&#8217;ils pourraient \u00eatre \u00e0 la fois plus efficaces cliniquement et plus rentables que les options de traitement pharmaceutiques et psychoth\u00e9rapeutiques actuelles.  <\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Priorit\u00e9s d&#8217;action<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Le gouvernement f\u00e9d\u00e9ral doit veiller \u00e0 ce que les substances psych\u00e9d\u00e9liques prometteuses pour le traitement de maladies telles que le syndrome de stress post-traumatique, la toxicomanie et d&#8217;autres troubles mentaux (LSD, psilocybine, MDMA, par exemple) soient retir\u00e9es de l&#8217;annexe J de la <em>loi sur les denr\u00e9es alimentaires et les m\u00e9dicaments<\/em>, afin qu&#8217;elles puissent \u00eatre facilement utilis\u00e9es dans la pratique clinique au fur et \u00e0 mesure que la recherche scientifique confirme leur potentiel m\u00e9dical et th\u00e9rapeutique.<\/li>\n\n\n\n<li>Le gouvernement f\u00e9d\u00e9ral collabore avec les \u00e9glises Sainto Daime et Uni\u00e3ode Vegetal, ainsi qu&#8217;avec les praticiens chamaniques, afin d&#8217;\u00e9tudier les possibilit\u00e9s de l\u00e9gitimer les usages c\u00e9r\u00e9moniels de l&#8217;ayahuasca et d&#8217;autres substances psychoactives similaires \u00e0 base de plantes, utilis\u00e9es \u00e0 des fins sacramentelles et de gu\u00e9rison populaire traditionnelle.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Pour en savoir plus<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/maps.org\/\" target=\"_blank\" rel=\"noreferrer noopener\">L&#8217;Association multidisciplinaire pour les \u00e9tudes psych\u00e9d\u00e9liques<\/a> (MAPS)<\/li>\n\n\n\n<li><a href=\"https:\/\/mapscanada.org\/\" target=\"_blank\" rel=\"noreferrer noopener\">MAPS &#8211; Canada<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.heffter.org\/\" target=\"_blank\" rel=\"noreferrer noopener\">L&#8217;Institut de recherche Heffter<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.beckleyfoundation.org\/beckley-imperial\/\" target=\"_blank\" rel=\"noreferrer noopener\">Le programme de recherche psychopharmacologique Beckley\/Imperial<\/a><\/li>\n<\/ul>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Une nouvelle fronti\u00e8re pour la m\u00e9decine curative Un article paru r\u00e9cemment dans le Journal de l&#8217;Association m\u00e9dicale canadienne, le8 septembre 2015, intitul\u00e9 &#8220;Psychedelic medicine : a re-emerging therapeutic paradigm&#8221;, illustre un regain d&#8217;int\u00e9r\u00eat pour l&#8217;exploration des b\u00e9n\u00e9fices de l&#8217;utilisation de substances psych\u00e9d\u00e9liques dans le traitement d&#8217;une s\u00e9rie de pathologies, notamment le syndrome de stress post-traumatique [&hellip;]<\/p>\n","protected":false},"author":53,"featured_media":17203,"parent":22088,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_crdt_document":"","footnotes":""},"class_list":["post-22188","page","type-page","status-publish","has-post-thumbnail","hentry"],"acf":[],"mb":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Psych\u00e9d\u00e9liques - Canadian Drug Policy Coalition<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.drugpolicy.ca\/fr\/les-problemes\/psychedeliques\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Psych\u00e9d\u00e9liques - Canadian Drug Policy Coalition\" \/>\n<meta property=\"og:description\" content=\"Une nouvelle fronti\u00e8re pour la m\u00e9decine curative Un article paru r\u00e9cemment dans le Journal de l&#8217;Association m\u00e9dicale canadienne, le8 septembre 2015, intitul\u00e9 &#8220;Psychedelic medicine : a re-emerging therapeutic paradigm&#8221;, illustre un regain d&#8217;int\u00e9r\u00eat pour l&#8217;exploration des b\u00e9n\u00e9fices de l&#8217;utilisation de substances psych\u00e9d\u00e9liques dans le traitement d&#8217;une s\u00e9rie de pathologies, notamment le syndrome de stress post-traumatique [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.drugpolicy.ca\/fr\/les-problemes\/psychedeliques\/\" \/>\n<meta property=\"og:site_name\" content=\"Canadian Drug Policy Coalition\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.drugpolicy.ca\/wp-content\/uploads\/2021\/11\/greg-rakozy-oMpAz-DN-9I-unsplash-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/les-problemes\\\/psychedeliques\\\/\",\"url\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/les-problemes\\\/psychedeliques\\\/\",\"name\":\"Psych\u00e9d\u00e9liques - Canadian Drug Policy Coalition\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/mail.canadiandrugpolicy.ca\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/les-problemes\\\/psychedeliques\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/les-problemes\\\/psychedeliques\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.drugpolicy.ca\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/greg-rakozy-oMpAz-DN-9I-unsplash-scaled.jpg\",\"datePublished\":\"2026-01-22T02:40:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/les-problemes\\\/psychedeliques\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/les-problemes\\\/psychedeliques\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/les-problemes\\\/psychedeliques\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.drugpolicy.ca\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/greg-rakozy-oMpAz-DN-9I-unsplash-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/www.drugpolicy.ca\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/greg-rakozy-oMpAz-DN-9I-unsplash-scaled.jpg\",\"width\":2560,\"height\":1707,\"caption\":\"(Unsplash)\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/les-problemes\\\/psychedeliques\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Les probl\u00e8mes\",\"item\":\"https:\\\/\\\/drugpolicy.ca\\\/fr\\\/les-problemes\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Psych\u00e9d\u00e9liques\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/mail.canadiandrugpolicy.ca\\\/#website\",\"url\":\"https:\\\/\\\/mail.canadiandrugpolicy.ca\\\/\",\"name\":\"Canadian Drug Policy Coalition\",\"description\":\"Change policy. Save lives.\",\"publisher\":{\"@id\":\"https:\\\/\\\/mail.canadiandrugpolicy.ca\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/mail.canadiandrugpolicy.ca\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/mail.canadiandrugpolicy.ca\\\/#organization\",\"name\":\"Canadian Drug Policy Coalition\",\"url\":\"https:\\\/\\\/mail.canadiandrugpolicy.ca\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/mail.canadiandrugpolicy.ca\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/drugpolicy.ca\\\/wp-content\\\/uploads\\\/2019\\\/04\\\/CDPC-logo-white-on-red-150-dpi.jpg\",\"contentUrl\":\"https:\\\/\\\/drugpolicy.ca\\\/wp-content\\\/uploads\\\/2019\\\/04\\\/CDPC-logo-white-on-red-150-dpi.jpg\",\"width\":332,\"height\":333,\"caption\":\"Canadian Drug Policy Coalition\"},\"image\":{\"@id\":\"https:\\\/\\\/mail.canadiandrugpolicy.ca\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Psych\u00e9d\u00e9liques - Canadian Drug Policy Coalition","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.drugpolicy.ca\/fr\/les-problemes\/psychedeliques\/","og_locale":"fr_FR","og_type":"article","og_title":"Psych\u00e9d\u00e9liques - Canadian Drug Policy Coalition","og_description":"Une nouvelle fronti\u00e8re pour la m\u00e9decine curative Un article paru r\u00e9cemment dans le Journal de l&#8217;Association m\u00e9dicale canadienne, le8 septembre 2015, intitul\u00e9 &#8220;Psychedelic medicine : a re-emerging therapeutic paradigm&#8221;, illustre un regain d&#8217;int\u00e9r\u00eat pour l&#8217;exploration des b\u00e9n\u00e9fices de l&#8217;utilisation de substances psych\u00e9d\u00e9liques dans le traitement d&#8217;une s\u00e9rie de pathologies, notamment le syndrome de stress post-traumatique [&hellip;]","og_url":"https:\/\/www.drugpolicy.ca\/fr\/les-problemes\/psychedeliques\/","og_site_name":"Canadian Drug Policy Coalition","og_image":[{"width":2560,"height":1707,"url":"https:\/\/www.drugpolicy.ca\/wp-content\/uploads\/2021\/11\/greg-rakozy-oMpAz-DN-9I-unsplash-scaled.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.drugpolicy.ca\/fr\/les-problemes\/psychedeliques\/","url":"https:\/\/www.drugpolicy.ca\/fr\/les-problemes\/psychedeliques\/","name":"Psych\u00e9d\u00e9liques - Canadian Drug Policy Coalition","isPartOf":{"@id":"https:\/\/mail.canadiandrugpolicy.ca\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.drugpolicy.ca\/fr\/les-problemes\/psychedeliques\/#primaryimage"},"image":{"@id":"https:\/\/www.drugpolicy.ca\/fr\/les-problemes\/psychedeliques\/#primaryimage"},"thumbnailUrl":"https:\/\/www.drugpolicy.ca\/wp-content\/uploads\/2021\/11\/greg-rakozy-oMpAz-DN-9I-unsplash-scaled.jpg","datePublished":"2026-01-22T02:40:38+00:00","breadcrumb":{"@id":"https:\/\/www.drugpolicy.ca\/fr\/les-problemes\/psychedeliques\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.drugpolicy.ca\/fr\/les-problemes\/psychedeliques\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.drugpolicy.ca\/fr\/les-problemes\/psychedeliques\/#primaryimage","url":"https:\/\/www.drugpolicy.ca\/wp-content\/uploads\/2021\/11\/greg-rakozy-oMpAz-DN-9I-unsplash-scaled.jpg","contentUrl":"https:\/\/www.drugpolicy.ca\/wp-content\/uploads\/2021\/11\/greg-rakozy-oMpAz-DN-9I-unsplash-scaled.jpg","width":2560,"height":1707,"caption":"(Unsplash)"},{"@type":"BreadcrumbList","@id":"https:\/\/www.drugpolicy.ca\/fr\/les-problemes\/psychedeliques\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.drugpolicy.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Les probl\u00e8mes","item":"https:\/\/drugpolicy.ca\/fr\/les-problemes\/"},{"@type":"ListItem","position":3,"name":"Psych\u00e9d\u00e9liques"}]},{"@type":"WebSite","@id":"https:\/\/mail.canadiandrugpolicy.ca\/#website","url":"https:\/\/mail.canadiandrugpolicy.ca\/","name":"Canadian Drug Policy Coalition","description":"Change policy. Save lives.","publisher":{"@id":"https:\/\/mail.canadiandrugpolicy.ca\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mail.canadiandrugpolicy.ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/mail.canadiandrugpolicy.ca\/#organization","name":"Canadian Drug Policy Coalition","url":"https:\/\/mail.canadiandrugpolicy.ca\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/mail.canadiandrugpolicy.ca\/#\/schema\/logo\/image\/","url":"https:\/\/drugpolicy.ca\/wp-content\/uploads\/2019\/04\/CDPC-logo-white-on-red-150-dpi.jpg","contentUrl":"https:\/\/drugpolicy.ca\/wp-content\/uploads\/2019\/04\/CDPC-logo-white-on-red-150-dpi.jpg","width":332,"height":333,"caption":"Canadian Drug Policy Coalition"},"image":{"@id":"https:\/\/mail.canadiandrugpolicy.ca\/#\/schema\/logo\/image\/"}}]}},"mfb_rest_fields":["title","yoast_head","yoast_head_json"],"_links":{"self":[{"href":"https:\/\/www.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/pages\/22188","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/users\/53"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/comments?post=22188"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/pages\/22188\/revisions"}],"predecessor-version":[{"id":22189,"href":"https:\/\/www.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/pages\/22188\/revisions\/22189"}],"up":[{"embeddable":true,"href":"https:\/\/www.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/pages\/22088"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/media\/17203"}],"wp:attachment":[{"href":"https:\/\/www.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/media?parent=22188"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}